Regencell Bioscience Holdings Limited Investor Relations Material
Latest events
Q4 2024
25 Oct, 2024
Q4 2023
27 Oct, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Regencell Bioscience Holdings Limited
Access all reports
Regencell Bioscience Holdings Limited is a biotechnology company focused on developing traditional Chinese medicine-based treatments for neurocognitive disorders and degenerative conditions. The company’s research aims to address conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), utilizing natural and holistic treatment approaches. Regencell's therapies are grounded in traditional medical practices, combined with modern scientific methods, to offer alternative treatment options for patients with these neurological conditions. The company is headquartered in Hong Kong, and its shares are listed on the Nasdaq.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
RGC
Country
🇺🇸 United States